Prospera™ Evidence in Heart and Lung Transplantation Featured Across 17 Presentations at ISHLT
Natera, Inc. announced extensive evidence supporting its Prospera test at the 2026 ISHLT Annual Meeting, with 17 abstracts including six oral presentations, emphasizing its clinical utility in heart and lung transplantation.
AUSTIN, Texas–(BUSINESS WIRE)–Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a broad body of evidence supporting its Prospera test at the 2026 International Society for Heart and Lung Transplantation (ISHLT) Annual Meeting. Prospera will be featured in 17 abstracts, including six oral presentations. Together with academic colleagues, Natera will highlight Prospera’s expanding clinical utility in heart and lung transplantation, spanning re